Alkermes (ALKS) Depreciation & Amortization (CF) (2010 - 2026)

Alkermes' (ALKS) quarterly Depreciation & Amortization (CF) came in at $19.4 million in Q1 2026, up 161.81% year-on-year from $7.4 million in Q1 2025, and up 405.17% on a QoQ basis from $3.8 million in Q4 2025.

Alkermes (ALKS) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $19.4 million in Q1 2026.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 161.81% year-over-year to $19.4 million in Q1 2026; TTM through Mar 2026 was $39.2 million, a 40.42% increase from a year earlier, with the FY2025 full-year figure at $27.2 million, down 4.79% from the prior year.
  • Depreciation & Amortization (CF) for Q1 2026 stood at $19.4 million, up from $3.8 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for ALKS reached as high as $19.7 million in Q4 2022 and fell as low as $3.8 million in Q4 2025.
  • Historically, Depreciation & Amortization (CF) has averaged $13.4 million across 5 years, with a median of $18.5 million in 2023.
  • Across the five-year window, Depreciation & Amortization (CF) plunged 64.98% in 2024 and jumped 161.81% in 2026, its largest moves.
  • Year by year, Depreciation & Amortization (CF) stood at $19.7 million in 2022, then fell by 5.77% to $18.5 million in 2023, then slumped by 63.07% to $6.8 million in 2024, then tumbled by 43.83% to $3.8 million in 2025, then soared by 405.17% to $19.4 million in 2026.
  • Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $19.4 million in Q1 2026, $3.8 million in Q4 2025, and $8.1 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 239.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 119.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 1.04 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 22.60 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 676.10 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 7.20 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 172.00 Mn
10 Alkermes 9.72 Bn 9.21 Bn 331.33 Mn 19.43 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 19.43 Mn
Mar 31, 2026 19.43 Mn
Dec 31, 2025 3.85 Mn
Dec 31, 2025 3.85 Mn
Sep 30, 2025 8.08 Mn
Sep 30, 2025 8.08 Mn
Jun 30, 2025 7.82 Mn
Jun 30, 2025 7.82 Mn
Mar 31, 2025 7.42 Mn
Mar 31, 2025 7.42 Mn
Dec 31, 2024 6.85 Mn
Dec 31, 2024 6.85 Mn
Sep 30, 2024 6.97 Mn
Sep 30, 2024 6.97 Mn
Jun 30, 2024 6.66 Mn
Jun 30, 2024 6.66 Mn
Mar 31, 2024 8.06 Mn
Mar 31, 2024 8.06 Mn
Dec 31, 2023 18.54 Mn
Dec 31, 2023 18.54 Mn